Anaptysbio (ANAB) Operating Leases (2021 - 2026)

Anaptysbio has reported Operating Leases for 6 years, with the latest figure at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 26.21% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 26.21% YoY), and the FY2025 full-year result was $12.0 million, down 14.74% from the prior year.
• Operating Leases for Q1 2026 stood at $11.5 million, down from $12.0 million in the prior quarter.
• The five-year high for Operating Leases was $20.6 million in Q1 2022, with the low at $11.5 million in Q1 2026.
• Historically, Operating Leases has averaged $16.3 million across 5 years, with a median of $16.5 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases gained 0.01% — and 2026, when it dropped 26.21%.
• Anaptysbio's Operating Leases stood at $17.8 million in 2022, then retreated by 9.97% to $16.0 million in 2023, then retreated by 12.0% to $14.1 million in 2024, then decreased by 14.74% to $12.0 million in 2025, then declined by 4.48% to $11.5 million in 2026.
• The last three Operating Leases figures came in at $11.5 million (Q1 2026), $12.0 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.